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Abstract
Background: Retinoblastoma is caused by compound heterozygosity or homozygosity of retinoblastoma gene
(RB1) mutations. In germline retinoblastoma, mutations in the RB1 gene predispose individuals to increased cancer
risks during development. These mutations segregate as autosomal dominant traits with high penetrance (90%).
Methods: We screened 30 family members from one family using high resolution melting assay and DNA direct
sequencing for mutations in the RB1 gene. We evaluate the phenotype and penetrance of germline mutations of
the RB1 gene in a large Taiwanese family.
Results: The molecular analysis and clinical details of this family showed phenotypic variability associated with the p.
V654L mutation in exon 19 of the RB1 gene in 11 family members. The phenotype varied from asymptomatic to
presence of a unilateral tumor. Only four individuals (2 males and 2 females) developed unilateral retinoblastoma,
which resulted in calculated low penetrance of 36% (4/11). The four individuals with retinoblastoma were diagnosed
before the age of three years. None of their relatives exhibited variable severity or bilateral retinoblastoma.
Conclusions: The diseased-eye ratio for this family was 0.36, which is lower than current estimates. This suggests
that the RB1 p.V654L mutation is a typical mutation associated with low penetrance.
Background
Retinoblastoma (OMIM +180200) is a rare eye cancer of
the developing retina in early childhood, typically before
the age of five years, with an incidence of 1 in 20,000 live
births [1,2]. Mutations of the retinoblastoma (RB1) gene,
which is the first tumor suppressor gene located on chro-
mosome 13q14, regulates the cell-cycle G1/S check
point, resulting in either malignant retinoblastoma or
benign retinoma [3]. The RB1 gene comprises 27 exons
across 180 kb and transcribes 4.8 kb of messenger RNA
(mRNA) into a protein of 928 amino acids [4]. Germline
mutations in RB1 gene predispose carriers to retinoblas-
toma tumors, resulting from loss of heterozygosity [5],
which is described in Knudson’s two-hit hypothesis [6].
Due to its high penetrance (over 90%), hereditary retino-
blastoma is transmitted as an autosomal dominant trait,
which accounts for 40% of cases, presenting with bilateral
retinoblastoma because of high expressivity. The remain-
ing 60% of RB1 non-intermediary germline mutations
often present as sporadic cases of unilateral retinoblas-
toma, without family history of retinoblastoma [7].
To date, a total of 2,508 RB1 DNA variants have been
registered in the Leiden Open Variation Database
(LOVD), including 1,790 substitutions, 502 deletions, 131
duplications, 53 insertions, 28 deletion/insertions 1 var-
iants with 2 changes in 1 allele, and 3 complex variants.
Although more than 90% of germline mutations in one
RB1 allele in individuals may cause cancerous tumors of
the retina, previous investigations show that some families
have extremely low penetrance of retinoblastoma [8,9].
The low penetrance of RB1 mutations is due to reduced
expressivity. The distinct mutations within the RB1 gene
associated with low penetrance retinoblastoma include a
point mutation at codon 661 of exon 20 [9,10], a 3-bp
deletion in exon 16 that results in the deletion of Asn480
[9], a 4-kb deletion involving exons 24 and 25 [11], and a
splicing mutation at the last base of exon 21 [12].
In this study, we performed clinical assessments and
molecular analyses in a large Taiwanese family with
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retinoblastoma. Clinical assessment and molecular ana-
lyses included the high resolution melting assay followed
by DNA direct sequencing in an apparently sporadic
index case with unilateral retinoblastoma, which led to
identification of the c.1960 G>T mutation in exon 19 of
the RB1 gene in this family. The aim of the current
study was to assess the phenotype and penetrance of the
germline RB1 p.V654L mutation in all members of the
family.
Methods
Subjects and DNA Extraction
All study DNA samples were obtained from the Depart-
ment of Medical Genetics, National Taiwan University
Hospital. Genetic counseling was provided to all partici-
pating family members and informed consent for partici-
pating in the study was obtained from each family
member (or guardian) under the authority of the Institu-
tional Ethics Committee of National Taiwan University
Hospital. Members of this pedigree were counseled to
identify both personal and family medical histories of reti-
noblastoma. Genomic DNA of 30 individuals was
extracted from peripheral whole blood using the Chema-
gic DNA Blood Kit (Chemagen, Baesweiler, Germany)
according to the manufacturer’s instructions.
Magnetic resonance imaging (MRI) or computerized
tomography (CT) was performed to diagnosis only one
tumor (unifocal) in only one eye or multiple tumors in one
eye (multifocal), to examine only one eye affected (unilat-
eral retinoblastoma) or both eyes affected (bilateral retino-
blastoma), and to confirm the stage of retinoblastoma.
Polymerase Chain Reaction (PCR)
The coding region of the RB1 gene was amplified based
on GenBank NC_000013 as the reference sequence using
specific forward (5’-atc ttt ccc agc ttg cat tt-3’) and
reverse primers (5’-cat gat ttg aac cca gtc agc-3’). PCR
was performed in a total volume of 10 μL containing
50 ng of genomic DNA, 0.15 μM of each primer, 2X
LightCycler 480 High Resolution Melting Master Mix
(Roche Diagnostics, Mannheim, Germany) in 2.5 mM
MgCl2 as provided by the manufacturer. PCR amplicons
were amplified in a multiblock system thermocycler
(ThermoHybaid, Ashford, UK) using a standard PCR
program. The protocol consisted of an initial denatura-
tion at 95°C for 10 min, followed by 35 cycles consisting
of denaturation at 94°C for 30 s, annealing at 50°C for
30 s, and extension at 72°C for 45 s, and then a final
extension step at 72°C for 10 min.
High resolution Melting Assay
The melting step was appended to the amplification step
(completely denatured at 95°C, cooled to 65°C at a ther-
mal transition rate of 4.4°C/s) and then heated to 95°C
at a thermal transition rate of 2.2°C/s with continuous
fluorescence monitoring on the LightCycler 480 (Roche
Diagnostics). The melting curve data were analyzed with
the gene scanning module software, version 1.3 (Roche
Diagnostics). The melting curves were then converted to
melting peaks by plotting the negative derivative of the
fluorescence with respect to temperature against tem-
perature (–dF/dT vs temperature).
DNA sequencing
PCR products were purified by solid-phase extraction
and bi-directionally sequenced using the Taq DyeDeoxy
Terminator Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA, USA). Sequencing reactions were sepa-
rated on a PE Biosystems 373A/3100 sequencer.
Results
The index case, a 16-year old boy, was referred for a reti-
noblastoma evaluation at the age of 2 years (IV-16, Figure
1). The clinical diagnosis, made by MRI examination of
the left eye (unilateral) showed the typical clinical features
of retinoblastoma in the left eye. After comprehensive
genetic counseling with the proband, the family history
was positive for retinoblastoma. The pedigree of this large
family is shown in Figure 1. Clinically, seven family mem-
bers (III-1, III-2, III-3, III-15, IV-3, IV-16, and IV-19)
developed unilateral retinoblastoma.
Because the proband’s family history was positive for
retinoblastoma, the detection rate of molecular genetic
testing was at least 90%. Therefore, genotyping was per-
formed on the proband by PCR amplification and subse-
quent high resolution melting assay. DNA analysis
revealed a mutation in the RB1 gene, c.1960 G>T located
on exon 19, a missense mutation, which resulted in a
change in the residue from valine to leucine (Figure 2).
This mutation was identified previously and is known to
be pathogenic [12]. Subsequently, the 29 family members
(the members denoted by ‘#’ in Figure 1) of the index
case consented to participate in this study. Comprehen-
sive mutations testing as well as retinoblastoma examina-
tions were performed to identify both genotypes and
phenotypes. Screening procedures in those at-risk family
members showed that genotypes of 19 homozygous wild
type (the members with # mark but without * mark) and
an additional 10 heterozygous germ-line mutations (the
members with # and * marks simultaneously in Figure 1)
were identified and consented to participate in clinical
examinations. Only four individuals, including the index
case (two males and two females), developed unilateral
retinoblastoma (the members in solid black), and seven
asymptomatic subjects carry a germ-line mutation in one
RB1 allele (the members with the slanted line). Further-
more, the ages of these seven mutation carriers without
retinoblastoma are greater than 20 years of age. We
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Figure 1 The pedigree of a Taiwanese family with retinoblastoma. The arrow shows the index case. The black symbols denote the
individuals with unilateral retinoblastoma and the slanted lines denote the asymptomatic individuals with RB1 p.V654L mutations. The ‘#’ marks
the family members who were tested, and ‘*’ marks individuals with the p.V654L mutation. The RB1 p.V654L mutation was identified in members
II-3, III-3, III-6, III-9, III-10, III-15, IV-3, IV-13, IV-14, IV-16, and IV-22.
Figure 2 The genetic analyses of RB1 gene. (A) Exon 19 of the RB1 gene was analyzed in 30 family members and 20 unaffected individuals
by high-resolution melting analysis. (B) After detection of the variant by high-resolution melting analysis, a derivative plot (-dF/dT vs
temperature) of exon 19 of the RB1 gene was constructed. (C) Sequencing confirmed that the wild type cluster and the c.1960 G>T clusters
were different.
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presume the chance that these carriers will develop reti-
noblastoma later is low because retinoblastoma is rarely
diagnosed after the age of 5 years and is typically diag-
nosed before the age of 3 years. Only a few cases of diag-
nosis after the age of 5 years are published.
The father of the index case (III-10), a 48-year old
man, had the inherited RB1 p.V654L mutation, but
without any suspicious clinical symptoms of retinoblas-
toma. Patients III-3, III-15, and VI-3, a 45-year old man,
a 39-year old woman, and a 20-year old woman, are the
uncle, aunt, and cousin of the index case, respectively,
who had inherited the disease-causing mutation
(p.V654L mutation). All of them had unilateral retino-
blastoma in the left eye and were diagnosed with retino-
blastoma before the age of 3 years. After surgical
removal of the retinoblastomas, these affected indivi-
duals (including the index case) survived. In particular,
none of them exhibited variable severity or bilateral reti-
noblastoma. In addition, they had no secondary tumors,
especially osteosarcoma, which typically affects signifi-
cant numbers of survivors of hereditary retinoblastoma.
The penetrance in this family is 4/11 (36%) among the
available members and none of them has bilateral reti-
noblastoma, which is indicative of low expressivity for
the germline RB1 c.1906 G>T mutation. The diseased-
eye ratio for this family is 0.36, which is lower than typi-
cal of low penetrance retinoblastoma families [9].
Discussion
This study describes a large Taiwanese family with retino-
blastoma, with the germline RB1 p.V654L mutation. The
family underwent comprehensive clinical examinations
and genetic screenings, as well as genetic counseling. Clin-
ical and genetic evaluations of the family members
revealed that only four of the 11 individuals who carried
the p.V654L mutation in one RB1 allele developed unilat-
eral retinoblastoma, yielding a penetrance of only 36%.
The ratio between symptomatic males and females is 1:1.
The penetrance is lower than that of previous reports of
individuals with RB1 null alleles. Although we did not ana-
lyze the expression of the p.V654L mutation at the RNA
level, the reduced penetrance could be explained by a
non-truncating mutation in which the resulting retinoblas-
toma protein is partially inactivated. The RB1 p.V654L
mutation is located on the B pocket domain of the pRB
protein, which forms a functional repressor motif with the
A pocket domain, important in the retina. Many missense
mutations are located in the domains A and B affecting its
structural folding and stability. Because valine and leucine
are both hydrophobic, non-polar amino acids, the mis-
sense is not likely to have a significant effect. The c.1960G
> T mutation changes the final base of exon 19, and
reduces the splicing score from 89 to 76.4 [13]. According
to the previous study [14], the p.V654L mutation is in fact
a splice mutation. The low-penetrance of c.1960G>C
could result from the splicing mutation affecting only the
last nucleotide of exon 19 [15]. The splicing machinery
could alternate between the defective missense splicing
(p.V654L mutation) and inactivation and skipping of exon
21 in the pocket box domain of RB1. This hypothesis
could be why the penetrance of this mutation is so low in
this particular family.
Speculative explanations for the low penetrance of reti-
noblastoma include the possibility that the incidence of
somatic mutation, recombination, and non-disjunction,
encourage the retention of the remaining normal allele in
all retinal cells in carriers of a germ-line mutation [16].
Another possibility is that additional genetic events
beyond the homozygous inactivation of the retinoblas-
toma gene are required to produce a retinoblastoma in
some individuals, described as the three-hit theory [11].
Alternatively, in some families, there may be either a sec-
ond retinoblastoma focus operating by a different
mechanism to predispose weakly to this cancer or per-
haps one or more modulator genes that reduce the risk
in such carriers (host resistance factors) [17,18]. The
weak-allele hypothesis [19] is that the inherited low pene-
trance retinoblastoma allele is partially, but not comple-
tely, impaired [20]. Loss of heterozygosity would result in
two copies of the weak allele, which would still be suffi-
ciently active to prevent tumorigenesis. Tumors would
arise only when the second mutation is a null, resulting
in a completely inactivated allele. Mutation affecting reg-
ulatory sequences in the RB1 promoter also reduce the
expression of normal Rb protein below a certain thresh-
old level necessary for tumor suppression function [21].
Conclusions
In summary, we describe a large and extensively
screened family with a germline RB1 p.V654L mutation.
Though the underlying molecular mechanisms in cases
of familial retinoblastoma with low penetrance and vari-
able expressivity are not well understood, mutation
identification permits accurate genetic counseling, with-
out which the developing retinoblastoma tumors might
be missed in children of families with low penetrance,
screened clinically on the basis of conventional risk
estimates.
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